Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageArtivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Business segments
Q1 2026 · $116.3MThe company’s own SEC segment disclosure.
- Aortic Stent Grafts$44.4M38%
- On X$26.0M22%
- Preservation Services$24.9M21%
- Surgical Sealants$18.8M16%
- Other Products$2.3M2%
Artivion, Inc. (AORT) reported revenue of $116M in Q1 2026 (quarter ended March 31, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 65% and net income of $1.4M (1.2% of revenue). For the full year FY2025, revenue was $441M (+14% year on year) and net income $9.8M. Its largest product in 2026-Q1 was Aortic Stent Grafts at $44M, 38% of the disclosed total, just ahead of On X at 22%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.